Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab

Schoe, Abraham; Laan-Baalbergen, Nicole E. Van Der; Huizinga, Tom W J; Breedveld, Ferdinand C.; Laar, Jacob M van

doi:10.1002/art.21716

Cited by 62 publications

(32 citation statements)

References 13 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the clinical course and the outcomes of these cases differ. Similar to our patient, one of the other patients improved after medium or high dose of steroid treatment [8], but the other patient did not improve and died of pulmonary infection [9]. Fatal exacerbation of IP case with systemic sclerosis treated with adalimumab has been reported [20].…”

Section: Discussionsupporting

confidence: 73%

“…Two other RA cases of adalimumab-associated IP have been reported recently [8,9]. In these cases, the patients were [65 years of age, they tested positive for rheumatoid factor, and they did not have previous IP; in addition, the IP occurred within several months following the initiation of adalimumab treatment.…”

Section: Discussionmentioning

confidence: 96%

“…To date, IP has been reported as an AE of treatment with anti-TNF-a agents, such as infliximab and eternercept [4][5][6][7]. However, there are only a few reports on adalimumabassociated IP [8,9].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis

Yamazaki

Isogai

Sakurai³

et al. 2010

Mod Rheumatol

View full text Add to dashboard Cite

A 64-year-old woman with rheumatoid arthritis (RA) began to complain of recurrent non-productive cough 5 months after starting adalimumab. The chest radiograph and high-resolution computed tomographic findings revealed diffuse ground-glass attenuation. Her clinical course suggested that interstitial pneumonia (IP) may have been induced by adalimumab, and she was successfully treated with a medium dose of corticosteroid. This case indicates that adalimumab-associated IP should be considered if a RA patient develops non-productive cough following adalimumab therapy.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis

Yamazaki

Isogai

Sakurai³

et al. 2010

Mod Rheumatol

View full text Add to dashboard Cite

show abstract

“…[30][31][32] Overall, interstitial pneumonias have been reported in at least 18 patients receiving various anti-TNF agents. 29 Sarcoidosis also has been reported in patients treated with anti-TNF agents.…”

Section: Etanerceptmentioning

confidence: 99%

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

“…These include bacterial infections, mycobacterial infections, fungal infections, cutaneous malignancies, exacerbations of congestive heart failure, and autoimmune diseases 1,2,3 . In addition, anecdotal reports have linked interstitial lung disease (ILD) and pulmonary fibrosis to etanercept 4 , infliximab 5 , or adalimumab 6,7 . Recently, one study reported no clear pattern of causal relationship of treatment with infliximab and hospitalization for ILD in patients with rheumatoid arthritis (RA) 8 .…”

Section: To the Editormentioning

confidence: 99%

Rapidly Fatal Pulmonary Fibrosis in a Patient with Psoriatic Arthritis Treated with Adalimumab

Cohen¹,

Capell²,

Kinniry³

et al. 2011

J Rheumatol

View full text Add to dashboard Cite

Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab

Cited by 62 publications

References 13 publications

A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis

A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Rapidly Fatal Pulmonary Fibrosis in a Patient with Psoriatic Arthritis Treated with Adalimumab

Contact Info

Product

Resources

About